Open AccessSafety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
Author(s) -
Shelly Senders,
Nicola P. Klein,
Erik Lamberth,
Allison Thompson,
Jelena Drozd,
James Trammel,
Yahong Peng,
Peter C. Giardina,
Kathrin U. Jansen,
William C. Gruber,
Daniel A. Scott,
Wendy Watson
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003277
Subject(s) - medicine , pneumococcal conjugate vaccine , immunogenicity , tolerability , adverse effect , serotype , pediatrics , population , immunology , immune system , streptococcus pneumoniae , antibiotics , environmental health , microbiology and biotechnology , biology
The development and widespread use of pneumococcal conjugate vaccines (PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the serotypes covered by PCVs may further reduce disease burden. A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) to those in the existing 13-valent PCV (PCV13). This phase 2 study evaluated the safety, tolerability and immunogenicity of PCV20 in healthy US infants.